Next-generation CRISPR screens – a powerful technology to advance drug target identification and validation

At Myllia, we utilize the CROP-Seq (for “CRISPR Droplet Sequencing”) workflow to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next generation CRISPR screens. Our powerful approach has broad applications in identifying novel drug targets, elucidating unknown mechanisms of actions of drugs and understanding genetic variants linked to disease risk.

We partner with biotech and pharma companies across the globe, and we perform high-throughput CRISPR screens in cancer cells or primary human T cells on a fee-for-service basis. All CRISPR screens using CRISPR KO, CRISPR interference or CRISPR activation workflows are specifically customized to the needs of our clients and we offer various read-outs (incl. fitness, FACS, flow cytometry, CITE-seq and single-cell transcriptomics) as well as computational biology analysis of NGS data. Finally, we cover end-to-end workflows from initial project design to wet-lab screening and the analysis of NGS data that is fully owned by our clients (no royalties, no strings attached).